CPI 360 manufacturers
- CPI-360
-
- $0.00 / 100mg
-
2024-07-22
- CAS:1802175-06-9
- Min. Order: 1mg
- Purity: 98
- Supply Ability: 100G
- CPI-360
-
- $1.00 / 1KG
-
2020-01-02
- CAS:1802175-06-9
- Min. Order: 1KG
- Purity: Min98% HPLC
- Supply Ability: g/kg/ton
|
| CPI 360 Basic information |
Product Name: | CPI 360 | Synonyms: | CPI 360;CPI360;CPI-360;CPI360;CPI 360;CPI-360 (R);1H-Indole-3-carboxamide, N-[(1,2-dihydro-4-methoxy-6-methyl-2-oxo-3-pyridinyl)methyl]-2-methyl-1-[(1R)-1-(tetrahydro-2H-pyran-4-yl)ethyl]- | CAS: | 1802175-06-9 | MF: | C25H31N3O4 | MW: | 437.53 | EINECS: | | Product Categories: | | Mol File: | 1802175-06-9.mol | |
| CPI 360 Chemical Properties |
Boiling point | 712.2±60.0 °C(Predicted) | density | 1.26±0.1 g/cm3(Predicted) | storage temp. | Store at -20°C | solubility | DMF: 10 mg/mL; DMSO: 25 mg/mL; Ethanol: 30 mg/mL; Ethanol:PBS (pH7.2) (1:7): 0.12 mg/mL | form | A crystalline solid | pka | 11.01±0.10(Predicted) |
| CPI 360 Usage And Synthesis |
Description | CPI-360 is a selective EZH2 inhibitor with IC50 values of 0.5 and 2.5 nM for wild-type EZH2 and Y641N mutant EZH2, respectively. It decreases cellular levels of H3K27me3 and H3K27me2 (EC50s = 56 and 65 nM, respectively), triggering cell cycle arrest and ultimately resulting in apoptosis in a large panel of non-Hodgkin’s lymphoma (NHL) cell lines. Twice daily, subcutaneous administration of 200 mg/kg of CPI-360 reduced tumor growth of KARPAS-422 xenografts in mice. |
| CPI 360 Preparation Products And Raw materials |
|